Syndax Pharmaceuticals (SNDX)

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

A(z) Syndax Pharmaceuticals, Inc. Common Stock (SNDX) részvény after-hours mai árfolyama , ami NaN% after-hours elmozdulást tükröz a piac legutóbbi zárása óta. A vállalat piaci kapitalizációja jelenleg 1,89 Mrd $, a napi kereskedési volumen pedig  részvény. A korábbi záró ár volt.

Készen állsz? Kövesd az alábbi lépéseket, vagy olvasd el útmutatónkat a(z) hogyan vásárolj Syndax Pharmaceuticals részvényt a Krakenen, kezdve 10 dollárral.